| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Aging and the Growth of Long-Term Care |
0 |
0 |
0 |
30 |
0 |
4 |
5 |
149 |
| Aging and the Growth of Long-Term Care |
0 |
0 |
0 |
243 |
6 |
12 |
14 |
1,306 |
| An Economic Evaluation of the War on Cancer |
0 |
0 |
0 |
97 |
1 |
4 |
5 |
365 |
| Are the Young Becoming More Disabled? |
0 |
0 |
0 |
93 |
3 |
8 |
9 |
355 |
| Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk-Transfer |
0 |
0 |
1 |
153 |
6 |
11 |
14 |
556 |
| Does Medicare Benefit the Poor? New Answers to an Old Question |
0 |
0 |
0 |
67 |
4 |
6 |
8 |
386 |
| Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
0 |
0 |
0 |
85 |
1 |
5 |
7 |
42 |
| Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
0 |
0 |
0 |
23 |
4 |
5 |
9 |
45 |
| Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey |
0 |
0 |
0 |
55 |
4 |
6 |
6 |
263 |
| Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? |
0 |
0 |
0 |
6 |
6 |
7 |
14 |
55 |
| Effects of expanding health screening on treatment – What should we expect? What can we learn? |
0 |
0 |
0 |
6 |
3 |
5 |
6 |
60 |
| Evaluation of Medical Technologies with Uncertain Benefits |
0 |
0 |
0 |
48 |
0 |
2 |
5 |
48 |
| Food Prices and the Dynamics of Body Weight |
0 |
0 |
0 |
71 |
4 |
4 |
5 |
237 |
| HIV Breakthroughs and Risk Sexual Behavior |
0 |
0 |
0 |
84 |
5 |
6 |
7 |
641 |
| Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses |
0 |
0 |
0 |
13 |
6 |
7 |
9 |
62 |
| Health Insurance as a Two-Part Pricing Contract |
0 |
0 |
0 |
97 |
1 |
4 |
8 |
433 |
| Health and Access Effects of New Drugs: Combining Experimental and Non-Experimental Data |
0 |
0 |
0 |
52 |
1 |
3 |
4 |
195 |
| Insurance and Innovation in Health Care Markets |
0 |
1 |
1 |
139 |
6 |
13 |
16 |
483 |
| Insurance, Self-Protection, and the Economics of Terrorism |
0 |
0 |
0 |
289 |
6 |
7 |
13 |
899 |
| Insurer Bargaining and Negotiated Drug Prices in Medicare Part D |
0 |
0 |
0 |
32 |
9 |
12 |
13 |
161 |
| Insurers' Negotiating Leverage and the External Effects of Medicare Part D |
0 |
0 |
0 |
14 |
4 |
5 |
8 |
104 |
| Insurers’ Negotiating Leverage and the External Effects of Medicare Part D |
0 |
0 |
0 |
3 |
8 |
10 |
12 |
83 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
91 |
3 |
6 |
9 |
399 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
0 |
3 |
7 |
12 |
15 |
| International Differences in Longevity and Health and Their Economic Consequences |
0 |
0 |
0 |
35 |
4 |
6 |
8 |
130 |
| International Differences in Longevity and Health and their Economic Consequences |
0 |
0 |
0 |
55 |
3 |
6 |
12 |
180 |
| International Differences in Longevity and Health and their Economic Consequences |
0 |
0 |
0 |
51 |
3 |
4 |
5 |
268 |
| Mortality Risk, Insurance, and the Value of Life |
0 |
0 |
0 |
37 |
9 |
19 |
21 |
69 |
| Nonprofit Production |
0 |
0 |
0 |
0 |
2 |
4 |
5 |
200 |
| Nonprofit Production and Competition |
0 |
0 |
2 |
301 |
3 |
5 |
12 |
1,265 |
| Optimal Liability for Terrorism |
0 |
0 |
0 |
40 |
5 |
6 |
8 |
222 |
| Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D |
0 |
0 |
0 |
24 |
6 |
8 |
8 |
104 |
| Risk Preferences Over Health: Empirical Estimates and Implications for Healthcare Decision-Making |
0 |
0 |
0 |
15 |
6 |
9 |
10 |
19 |
| The Declining Quality of Teachers |
0 |
0 |
0 |
222 |
6 |
8 |
12 |
1,709 |
| The Effect of US COVID-19 Excess Mortality on Social Security Outlays |
0 |
0 |
6 |
6 |
11 |
14 |
20 |
20 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
492 |
5 |
14 |
16 |
1,619 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
0 |
4 |
7 |
11 |
15 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
89 |
3 |
10 |
13 |
382 |
| The Insurance Value of Medical Innovation |
0 |
0 |
1 |
34 |
5 |
5 |
7 |
112 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
1 |
3 |
1 |
5 |
7 |
776 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
234 |
5 |
5 |
7 |
1,782 |
| The Value of Medican and Pharmaceutical Interventions for Reducing Obesity |
0 |
0 |
0 |
29 |
4 |
7 |
9 |
173 |
| The Welfare Effects of Medical Malpractice Liability |
0 |
0 |
0 |
101 |
2 |
4 |
12 |
479 |
| The Welfare Effects of Public Drug Insurance |
0 |
0 |
0 |
77 |
4 |
7 |
9 |
295 |
| Time-Inconsistency and Welfare |
0 |
0 |
0 |
79 |
1 |
8 |
13 |
390 |
| Understanding Health Disparities Across Education Groups |
0 |
0 |
1 |
398 |
3 |
9 |
17 |
1,713 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
43 |
4 |
5 |
10 |
233 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
36 |
2 |
2 |
2 |
113 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
50 |
5 |
8 |
12 |
189 |
| Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market |
0 |
0 |
0 |
15 |
3 |
6 |
9 |
117 |
| Vaccine Allocation Priorities Using Disease Surveillance and Economic Data |
0 |
0 |
1 |
3 |
0 |
8 |
11 |
25 |
| Total Working Papers |
0 |
1 |
14 |
4,260 |
203 |
358 |
504 |
19,941 |
LogEc is hosted by the
Örebro University School of Business.